JARDIANCE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug JARDIANCE contains one active pharmaceutical ingredient (API):

1	Empagliflozin UNII HDC1R2M35U - EMPAGLIFLOZIN
	Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2). Empagliflozin improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption.
	Read more about Empagliflozin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JARDIANCE Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BK03		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Discover more medicines within A10BK03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10202Y, 10206E, 11281R, 11314L
BR	Câmara de Regulação do Mercado de Medicamentos	504514110019702, 504514110019802, 504514110019902, 504514110020002
CA	Health Products and Food Branch	02443937, 02443945
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	630-MEE-0115, 631-MEE-0115
EE	Ravimiamet	1648964, 1648975, 1648986, 1648997, 1649000, 1649011, 1649022, 1649033, 1649044, 1649099, 1649101, 1649112, 1649123, 1649134, 1649145, 1649156, 1649167, 1649178
ES	Centro de información online de medicamentos de la AEMPS	114930005, 114930014
FI	Lääkealan turvallisuus- ja kehittämiskeskus	106581, 110972, 526918, 541084
FR	Base de données publique des médicaments	67947145, 69963066
GB	Medicines & Healthcare Products Regulatory Agency	252389, 252401, 368047, 368050, 374409, 374410, 374412, 374413, 376687, 381422, 381423, 381425, 381426
HK	Department of Health Drug Office	64095, 64096
IE	Health Products Regulatory Authority	13256, 13257
IL	מִשְׂרַד הַבְּרִיאוּת	7596, 7597
IT	Agenzia del Farmaco	043443011, 043443023, 043443035, 043443047, 043443050, 043443062, 043443074, 043443086, 043443098, 043443100, 043443112, 043443124, 043443136, 043443148, 043443151, 043443163, 043443175, 043443187
JP	医薬品医療機器総合機構	3969023F1023, 3969023F2020
LT	Valstybinė vaistų kontrolės tarnyba	1071137, 1072776, 1073470, 1073471, 1073472, 1073473, 1073474, 1073475, 1073476, 1073477, 1073480, 1073481, 1073482, 1073483, 1073484, 1073485, 1073486, 1073487
NG	Registered Drug Product Database	C4-0225, C4-0226
Switch country to Nigeria in order to find specific presentations of JARDIANCE
NL	Z-Index G-Standaard, PRK	119407, 119415
NZ	Medicines and Medical Devices Safety Authority	16935, 16948
PL	Rejestru Produktów Leczniczych	100315976, 100315982
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W60940001, W60940002, W60940003, W60941001, W60941002, W60941003
SG	Health Sciences Authority	14686P, 14687P
TN	Direction de la Pharmacie et du Médicament	11533071, 11533072
TR	İlaç ve Tıbbi Cihaz Kurumu	8699693090119, 8699693090126
US	FDA, National Drug Code	0597-0152, 0597-0153, 50090-4384, 50090-4492, 55154-0411, 55154-0412, 70518-1986, 70518-2447, 71610-177
ZA	Health Products Regulatory Authority	48/21.2/0411, 48/21.2/1380